MedTrace Logo

Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

NCT01618266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 375

Last updated 2016-03-14

Study results available
· View outcomes & findings →

Summary

Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Interventions

DRUG

dexamethasone intravitreal implant

dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-04-30
Completion
2014-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01618266 on ClinicalTrials.gov